Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Richard Lussier, Terry Speed, Christine Cournoyer, and others

Premium

CLC Bio has hired Richard Lussier to serve as its director of business for the Americas. In his new role, Lussier will be responsible for developing the Copenhagen, Denmark-based company's presence in the region.

Prior to joining CLC Bio, Lussier served as VP of worldwide sales at RainDance Technologies. He also held leadership positions at Solexa (now part of Illumina); Fluidigm; Applied Biosystems (now part of Life Technologies); and Celera Genomics (now part of Quest Diagnostics).


Terry Speed, a bioinformatics professor at the Australian Walter and Eliza Hall Institute of Medical Research, has won the 2012 Thomson Reuters Citation Award in biochemistry and molecular biology.

Speed, who heads the institute's bioinformatics division, has developed new data-analysis techniques with applications in biological fields such as infection, immunity, inherited human diseases, and cancer.

His research interests include metabolic flux analysis; estimating 13C enrichment in time course experiments; and base calling for resequencing chips.


N-of-One said this week that it has tapped Christine Cournoyer to serve as its CEO.

The company also said that Jennifer Levin Carter, the company’s founder and current president, has taken on the additional responsibility of chief medical officer.

Prior to joining N-of-One, Cournoyer was president and chief operating officer of Picis, a provider of health information software solutions that was acquired by UnitedHealthcare in 2010. She also served as the managing director of Harte-Hanks, a database and analytics marketing company; president and COO of Lightbridge; senior vice president at Lotus Development; and she also previously held several senior management positions at IBM.

Cournoyer earned her bachelor's degree at the University of Massachusetts, Lowell, and received a master's in economics from Northeastern University.

Prior to launching N-of-One, Carter was a consultant and analyzed biotechnology, pharmaceutical, and medical device firms on behalf of investors. She also previously worked with Angel Healthcare Investors evaluating early-stage private companies and raising seed capital for startups.

Carter has bachelor's degrees in biochemistry and biophysics from Yale University. She also received her medical degree from Harvard Medical School and a public health degree from Harvard School of Public Health.


Ariana Pharma, a provider of an association rules-based clinical data analysis technology to the pharmaceutical industry, has appointed James Shanahan to serve as its vice president of business development.

Prior to joining the company, Shanahan helped found SynDevRx, an oncology-focused biotech company; and JAM Technologies, where he also served as VP of corporate development.

The company also said that it has opened a US office in Cambridge, Mass., to meet the growing demand for its technology.


The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.